B. Riley initiated coverage of Foghorn Therapeutics (FHTX) with a Buy rating and $10 price target. The firm says its investment thesis centers on the company’s strategy to inactivate or degrade ...

Foghorn Therapeutics (FHTX) has received a new Buy rating, initiated by B.Riley Financial analyst, Kalpit Patel. Kalpit Patel’s rating is based on Foghorn Therapeutics’ innovative approach to ...

CAMBRIDGE, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Foghorn ® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious ...

Intending to catch a chicken for his dinner, little Henery the Chicken Hawk ventures onto the farm of the eternally feuding Foghorn Leghorn and barnyard dog. Foghorn tries to dump a load of concrete ...

Hello Maine GeoLibrary Data Catalog Users. There is currently a partial outage on the process to download GIS data from the Data Catalog impacting the direct catalog discovery and download tools. Our ...